BibTex RIS Cite

Ultrasound-guided Injection of Botulinum Toxina In The Treatment of Sialorrhoea In Patient With Atypical Parkinson's Disease: Case Report

Year 2015, Issue: 3, 171 - 173, 01.09.2015

Elçin Aydın Hasan Yerli Tuğbahan Yılmaz Esin Gezmiş

Abstract

Sialorrhoea is a common symptom of Parkinson’s disease. Anticholinergic drugs used in the medical treatment of sialorrhoea is only partially effective and can cause intolerable side effects. Recently, it has been underlined that percutaneous injection of botulinum toxin is a effective method in the treatment of sialorrhoea in patients with Parkinson’s disease in this report, the percutaneous treatment of sialorrhoea, which is unresponsive to medical therapy, by ultrasound-guided botulinum toxin injection for 66 years old man with atypical Parkinson’s disease, were discussed in the light of the related literatüre

Keywords

sialorrhoea Parkinson’s disease botulinum toxin

References

  • Johnson H., Scott A. 6 Saliva Management. In: Cichero J.A.Y., Murdoch B.E., editors. Dysphagia: Foundation, Theory and Practice. John Wiley & Sons Ltd; West Sussex, UK: 2006, p. 126.
  • Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106: 93–6.
  • Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disorders 2001;7:329-32.
  • Koike Y, Takahashi A. Autonomic dysfunction in Parkinson`s disease. Eur Neurol 1997;38:8–12
  • Martignoni E, Pacchetti C, Micieli G, Nappi G. Autonomic disturbances in Parkinson`s disease and Shy-Drager syndrome. In: Korczyn AD editors. Handbook of Autonomic Nervous System Dysfunction. New York: Marcel Dekker 1995,p.235–52.
  • Pal PK, Calne DB, Calne S, Tsui JKC. Botulinum toxin A as treatment for drooling saliva in Parkinson's Disease. Neurology 2000;54:244–7.
  • Naver H, Aquilonius SM. The treatment of focal hyperhidrosis with botulinum toxin. Eur J Neurol 1997;4 (suppl 2):75–9.
  • Fuster Torres MA, Berini Aytes L, Gay Escoda C. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal 2007;12:E511–7.
  • Nobrega AC, Rodrigues B, Torres AC, Enzo A, Melo A. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease? Journal of Neurological Sciences 2007;253: 85-7
  • Jeung IS, Lee S, Kim HS, Yeo CK. Effect of Botulinum Toxin A Injection into the Salivary Glands for Sialorrhea in Children with Neurologic Disorders. Ann Rehabil Med 2012;36:340-6.
  • Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum. Toxins 2013;5:1010-31.

Atipik Parkinson Hastasının Siyalore Şikayetinin Ultrasonografi Eşliğinde Perkütan Botulinum Toksin Enjeksiyonu ile Tedavisi: Olgu Sunumu

Year 2015, Issue: 3, 171 - 173, 01.09.2015

Elçin Aydın Hasan Yerli Tuğbahan Yılmaz Esin Gezmiş

Abstract

Siyalore, Parkinson hastalığında sık görülen bir semptomdur. Siyalorenin medikal tedavisinde kullanılan antikolinerjik ilaçlar kısmi bir fayda gösterir ve hastanın tolere edemeyeceği yan etkilere sebep olabilirler. Son zamanlarda Parkinson hastalığında görülen siyalore tedavisinde perkutan botulinum toksin enjeksiyonunun etkin bir tedavi yöntemi olduğu vurgulanmaktadır. Bu yazıda, 66 yaşında atipik Parkinson tanısı olan hastada medikal tedaviye yanıt vermeyen siyalorenin ultrasonografi kılavuzluğunda botulinum toksini ile perkütan tedavisi literatür bilgileri eşliğinde tartışıldı

Keywords

siyalore Parkinson hastalığı botulinum toksini

References

  • Johnson H., Scott A. 6 Saliva Management. In: Cichero J.A.Y., Murdoch B.E., editors. Dysphagia: Foundation, Theory and Practice. John Wiley & Sons Ltd; West Sussex, UK: 2006, p. 126.
  • Dogu O, Apaydin D, Sevim S, Talas DU, Aral M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106: 93–6.
  • Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disorders 2001;7:329-32.
  • Koike Y, Takahashi A. Autonomic dysfunction in Parkinson`s disease. Eur Neurol 1997;38:8–12
  • Martignoni E, Pacchetti C, Micieli G, Nappi G. Autonomic disturbances in Parkinson`s disease and Shy-Drager syndrome. In: Korczyn AD editors. Handbook of Autonomic Nervous System Dysfunction. New York: Marcel Dekker 1995,p.235–52.
  • Pal PK, Calne DB, Calne S, Tsui JKC. Botulinum toxin A as treatment for drooling saliva in Parkinson's Disease. Neurology 2000;54:244–7.
  • Naver H, Aquilonius SM. The treatment of focal hyperhidrosis with botulinum toxin. Eur J Neurol 1997;4 (suppl 2):75–9.
  • Fuster Torres MA, Berini Aytes L, Gay Escoda C. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Med Oral Patol Oral Cir Bucal 2007;12:E511–7.
  • Nobrega AC, Rodrigues B, Torres AC, Enzo A, Melo A. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease? Journal of Neurological Sciences 2007;253: 85-7
  • Jeung IS, Lee S, Kim HS, Yeo CK. Effect of Botulinum Toxin A Injection into the Salivary Glands for Sialorrhea in Children with Neurologic Disorders. Ann Rehabil Med 2012;36:340-6.
  • Lakraj AA, Moghimi N, Jabbari B. Sialorrhea: Anatomy, Pathophysiology and Treatment with Emphasis on the Role of Botulinum. Toxins 2013;5:1010-31.
There are 11 citations in total.

Details

Primary Language Turkish
Journal Section Case Report
Authors

Elçin Aydın

Hasan Yerli

Tuğbahan Yılmaz

Esin Gezmiş

Publication Date September 1, 2015
Published in Issue Year 2015Issue: 3

Cite

EndNote Aydın E, Yerli H, Yılmaz T, Gezmiş E (September 1, 2015) Atipik Parkinson Hastasının Siyalore Şikayetinin Ultrasonografi Eşliğinde Perkütan Botulinum Toksin Enjeksiyonu ile Tedavisi: Olgu Sunumu. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 3 171–173.